Thomas Bachmann is New Chief Executive Officer of the Eppendorf Group
News Aug 04, 2015
Following the departure of Eppendorf's previous CEO, the company's Chief Financial Officer, Detmar Ammermann, had exercised the function of Spokesman of the Management Board on an interim basis in addition to his responsibilities as CFO.
Bachmann, who has been a member of the Eppendorf Supervisory Board since 2013, came to Eppendorf from his position as President of the Bruker BioSpin Group. He has been active in the life science sector since 2005, when he took on the overall management of the globally active Tecan Group, which is headquartered in Switzerland.
"We are very pleased that we have been able to win Thomas Bachmann as our Chief Executive Officer," said Klaus Fink, Chairman of the Supervisory Board of the Eppendorf Group. "He has demonstrated his expertise and his strategic foresight in many ways during more than 25 years of experience in international management positions."
Bachmann explains: "Eppendorf is an innovative, customer-oriented company with a strong, well-known brand and a global orientation, and it succeeds again and again in making important contributions to analytic, medical, diagnostic and life science laboratories. I am looking forward to working with Eppendorf's very competent and committed global management to develop the company sustainably and successfully in the years to come."
Research Collaboration Aims to Improve Breast Cancer Diagnosis Using AINews
A new project to explore how artificial intelligence (AI) could improve breast screening could potentially lead to more accurate detection of cancers.READ MORE
Dipstick Technology Enables Rapid Diagnosis AnywhereNews
A new Australian study has reported a revolutionary dipstick technology that allows DNA and RNA to be extracted from living organisms in as little as 30 seconds.READ MORE
New Simple Test Could Help Cystic Fibrosis Patients Find Best TreatmentNews
In a significant step toward personalized medicine for cystic fibrosis, a minimally-invasive technique shows promise as a fast, inexpensive indicator to help more patients access new treatments.READ MORE